#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Lindsay Wittmer Email
Director Quality . BioMagnetic Solutions
State College, PA
Locationl*******@biomagneticsolutions.com
Primary EmailHow to contact Lindsay Wittmer
Join and see Lindsay's contact info for free!Current Roles
Employees:
22Revenue:
$3.4MAbout
BioMagnetic Solutions (BioMag) is launching X-GRAFFE system, a state of the art immunomagnetic Cell Selection system for CAR-T cell & Gene Therapy (CGT) product mfg. X-GRAFFE will revolutionize the CGT cell selection process with its ultra high-performance, very rapid, gentle process & clean sheet of paper design & mkt. proven Ferrofluids. BioMag's X-GRAFFE Clinical-Scale Cell Selection system & nano-magnetic ferrofluids very rapidly yet very gently isolate cell subsets for CAR-T cell & gene therapy (GT) product mfg. X-GRAFFE is an elegant, closed system w/an array of patent-pending protocols & hardware. X-GRAFFE isolates CD34+ stem cells for GT & cell processing mfg. BioMag partners for its complementary array of cGMP mAbs, cytokines & CGT mfg. reagents. Founded in 2012 by Paul A. Liberti, PhD, BioMagnetic Solutions has a 30+ year history pioneering immuno-magnetic cell selection systems. Prior to BioMag, Liberti founded Immunicon (NASDAQ: IMMC) where he developed the Ferrofluids & immunomagnetic systems for CELLSEARCH® - the only FDA-approved Circulating Tumor Cell (CTC) assay that J&J/Janssen acq'd in 2008. BioMag's X-GRAFFE system leverages BioMag's market-tested** proprietary 6th-gen immunomagnetic Ferrofluids. BioMag also provides an array of proprietary cell selection reagents to the research market to scientists worldwide. Having pioneered Ferrofluid development & the design & mfg. of novel magnetic platform technologies for cell selection via our Immunicon DNA, BioMag brings 30+ cutting-edge R&D problem-solving years, IP & innovation to the design, synthesis & manufacture of Ferrofluids for path-breaking novel multi-parameter bio-magnetic selection systems. * CELLSEARCH® remains the only FDA-approved CTC assay for isolating & characterizing CTC - **16 years since its 2004 Immunicon introduction. CELLSEARCH© was acquired by J&J's Janssen Oncology SBU (formerly J&J's Veridex SBU). CELLSEARCH® is now owned by Menarini's Silicon Biosystems (2018).BioMagnetic Solutions Address
3058 Research DrState College, PA
United States